Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease
Andrew Satlin(Novartis (United States)), Donald A. Berry(Berry & Associates (United States)), Scott Berry(Queen's University), Chad J. Swanson(Eisai (United States)), Jinping Wang(Eisai (United States)), Veronika Logovinsky(Eisai (United States)), Shobha Dhadda(Eisai (United States))
Alzheimer s & Dementia Translational Research & Clinical Interventions
January 1, 2016
Cited by 87
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818